Biomarin Selling General Administrative from 2010 to 2025

BMRN Stock  USD 64.34  0.15  0.23%   
Biomarin Pharmaceutical Selling General Administrative yearly trend continues to be very stable with very little volatility. Selling General Administrative is likely to grow to about 542 M this year. During the period from 2010 to 2025, Biomarin Pharmaceutical Selling General Administrative quarterly data regression pattern had sample variance of 31745.2 T and median of  403,709,000. View All Fundamentals
 
Selling General Administrative  
First Reported
1999-03-31
Previous Quarter
140.2 M
Current Value
144.6 M
Quarterly Volatility
58.7 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Biomarin Pharmaceutical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biomarin Pharmaceutical's main balance sheet or income statement drivers, such as Depreciation And Amortization of 126 M, Interest Expense of 18 M or Selling General Administrative of 542 M, as well as many indicators such as Price To Sales Ratio of 8.18, Dividend Yield of 0.0 or PTB Ratio of 3.99. Biomarin financial statements analysis is a perfect complement when working with Biomarin Pharmaceutical Valuation or Volatility modules.
  
Check out the analysis of Biomarin Pharmaceutical Correlation against competitors.
To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.

Latest Biomarin Pharmaceutical's Selling General Administrative Growth Pattern

Below is the plot of the Selling General Administrative of Biomarin Pharmaceutical over the last few years. It is Biomarin Pharmaceutical's Selling General Administrative historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Biomarin Pharmaceutical's overall financial position and show how it may be relating to other accounts over time.
Selling General Administrative10 Years Trend
Slightly volatile
   Selling General Administrative   
       Timeline  

Biomarin Selling General Administrative Regression Statistics

Arithmetic Mean389,535,984
Geometric Mean288,261,825
Coefficient Of Variation45.74
Mean Deviation140,442,986
Median403,709,000
Standard Deviation178,171,803
Sample Variance31745.2T
Range677.4M
R-Value0.69
Mean Square Error17983.1T
R-Squared0.47
Significance0
Slope25,691,315
Total Sum of Squares476177.9T

Biomarin Selling General Administrative History

2025542 M
2024516.2 M
2023448.9 M
2022403.7 M
2021354.3 M
2020334.3 M
2019680.9 M

About Biomarin Pharmaceutical Financial Statements

Biomarin Pharmaceutical investors utilize fundamental indicators, such as Selling General Administrative, to predict how Biomarin Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Selling General Administrative516.2 M542 M
When determining whether Biomarin Pharmaceutical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biomarin Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biomarin Pharmaceutical Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biomarin Pharmaceutical Stock:
Check out the analysis of Biomarin Pharmaceutical Correlation against competitors.
To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.
You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
1.607
Earnings Share
1.66
Revenue Per Share
14.529
Quarterly Revenue Growth
0.283
Return On Assets
0.03
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.